About UNI-BIO GROUP Company

Liankang Biotechnology Group Limited (the “Company”) is a company listed on the main board of the Stock Exchange of Hong Kong Limited (stock code: 0690). The core business of the Company and its subsidiaries (collectively “Liankang” or the “Group”) is the research, development, manufacture and sale of innovative biological products that treat human diseases. Liankang is headquartered in Hong Kong, and its main operations are located in mainland China. The Group is strongly focused on research and development (“R&D”) and has established a team of highly qualified professionals. The Group also has two production plants certified by GMP (“Good Manufacturing Practice”) in Beijing and Shenzhen, respectively, which are responsible for producing the products we sell - voriconazole and epidermal growth factors. Currently, two newly prescribed drugs in the Group have entered or completed clinical trials. Insulin-stimulating hormone (“Uni-E4”) and human parathyroid hormone (1-34) (“Uni-PTH”) have completed all clinical tests. Among them, Uni-E4 mainly targets type 2 diabetics, especially those who are overweight. Uni-PTH is a treatment for postmenopausal women with osteoporosis (submitted and reviewed by the China Food and Drug Administration in April 2015). The Group's corporate philosophy is to improve our health by bringing high-quality science and treatment to patients. To this end, the Group is dedicated to better serving patients through cooperation, thus eventually becoming the “best partner” in China, bringing economic and important treatment plans to China.